Mallinckrodt PLC (NYSE:MNK) has received an average rating of “Hold” from the eighteen analysts that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $30.88.

Several research analysts have recently issued reports on the company. ValuEngine downgraded Mallinckrodt from a “sell” rating to a “strong sell” rating in a research note on Monday. Canaccord Genuity set a $40.00 price objective on Mallinckrodt and gave the company a “buy” rating in a research note on Monday, March 18th. Mizuho upped their price objective on Mallinckrodt to $26.00 and gave the company a “neutral” rating in a research note on Thursday, February 28th. SunTrust Banks initiated coverage on Mallinckrodt in a research note on Tuesday, March 19th. They issued a “hold” rating and a $23.00 price objective for the company. Finally, Morgan Stanley set a $32.00 target price on Mallinckrodt and gave the company a “hold” rating in a report on Thursday, February 28th.

Mallinckrodt stock opened at $15.13 on Friday. Mallinckrodt has a 1 year low of $13.45 and a 1 year high of $36.65. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.45 and a quick ratio of 1.17. The company has a market capitalization of $1.29 billion, a PE ratio of 1.89, a PEG ratio of 0.16 and a beta of 2.12.

Mallinckrodt (NYSE:MNK) last released its quarterly earnings data on Tuesday, May 7th. The company reported $1.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.73 by $0.21. Mallinckrodt had a positive return on equity of 14.22% and a negative net margin of 118.53%. The company had revenue of $791.00 million during the quarter, compared to the consensus estimate of $766.27 million. During the same quarter in the prior year, the firm posted $1.31 earnings per share. The firm’s revenue was up 4.7% compared to the same quarter last year. On average, sell-side analysts predict that Mallinckrodt will post 8.38 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in MNK. Martingale Asset Management L P boosted its holdings in Mallinckrodt by 52.7% in the third quarter. Martingale Asset Management L P now owns 75,456 shares of the company’s stock valued at $2,212,000 after acquiring an additional 26,030 shares during the last quarter. Teachers Advisors LLC boosted its holdings in shares of Mallinckrodt by 23.5% during the 3rd quarter. Teachers Advisors LLC now owns 203,721 shares of the company’s stock worth $5,971,000 after buying an additional 38,759 shares in the last quarter. Nordea Investment Management AB bought a new position in shares of Mallinckrodt during the 3rd quarter worth approximately $1,698,000. Legal & General Group Plc boosted its holdings in shares of Mallinckrodt by 18.3% during the 3rd quarter. Legal & General Group Plc now owns 172,157 shares of the company’s stock worth $5,045,000 after buying an additional 26,574 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Mallinckrodt by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 7,597,447 shares of the company’s stock worth $222,681,000 after buying an additional 174,836 shares in the last quarter.

Mallinckrodt Company Profile

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.

Further Reading: Momentum Investing

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.